Ischemia Reperfusion Articles & Analysis
7 news found
Carleton Hsia, NanoBlood: NanoBlood LLC has developed VitalHemeTM (nanoRBC), an innovative multifunctional neurovascular protective agent for the prevention and treatment of ischemia, reperfusion injury and damaging inflammatory reactions caused by superoxide generation. ...
McCully pioneered the approach of mitochondria augmentation and replacement at Harvard Medical School and the team has now set out to bring it about as a new treatment modality in ischemia-reperfusion injury, aging, and ...
McCully pioneered the approach of mitochondria augmentation and replacement at Harvard Medical School and the team has now set out to bring it about as a new treatment modality in ischemia-reperfusion injury, aging, and beyond. Since its founding cellvie has successfully expanded its team and operations close to Zürich. ...
Alex presented on the potential of mitochondria as a new treatment modality, not only for ischemia-reperfusion injury, but also for aging related degeneration. Loss of mitochondria function and mass has been reported in muscle degeneration and cellvie has been working to counter these developments with mitochondria transplantation. ...
The Amsel technology is a minimally invasive fine-needle delivery of a temporary clamp for fast, secure mechanical arterial occlusion with the ability to vary the degree of occlusion of the targeted vessel, minimizing the potential consequences of prolonged limb ischemia and reperfusion injury. When no longer required, the clamp can simply be removed, without the ...
James McCully, a cellvie AG co-founder, developed the approach at Harvard Medical School to ameliorate ischemia-reperfusion injury, which is the tissue damage caused when the blood supply returns after a period of ischemia. ...
This special orphan drug status comes with multiple benefits: Eligibility for market exclusivity for 7 years post approval Tax credits of 50% off the clinical drug testing cost awarded upon approval FDA fast-track for evaluation & FDA recommendations Pushing for medical breakthroughs since being founded in 2018, cellvie is leveraging the therapeutic potential of mitochondria to ...